Document:

THIS
NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THERULESANDREGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”)

 

 

US
$56,000.00

 

 

RICH
PHARMACEUTICALS, INC.

8%
CONVERTIBLE REDEEMABLE NOTE DUE JUNE 23, 2017

BACK
END NOTE

 

FOR
VALUE RECEIVED, Rich Pharmaceuticals, Inc. (the “Company”) promises to pay to the order of LG CAPITAL FUNDING,
LLC and its authorized successors and permitted as- signs ("Holder"), the aggregate principal face amount of
Fifty Six Thousand dollars exactly (U.S. $56,000.00) on June 23, 2017 ("Maturity Date") and to pay interest
on the principal amount out- standing hereunder at the rate of 8% per annum commencing on June 23, 2016. The interest will be
paid to the Holder in whose name this Note is registered on the records of the Company re- garding registration and transfers
of this Note. The principal of, and interest on, this Note are payable at 1218 Union Street, Suite #2, Brooklyn, NY 11225,
initially, and if changed, last appearing on the records of the Company as designated in writing by the Holder hereof from
time to time. The Company will pay each interest payment and the outstanding principal due upon this Note before or on the
Maturity Date, less any amounts required by law to be deducted or withheld, to the Holder of this Note by check or wire
transfer addressed to such Holder at the last address appearing on the records of the Company. The forwarding of such check
or wire transfer shall constitute a payment of outstanding principal hereunder and shall satisfy and discharge the liability
for principal on this Note to the extent of the sum represented by such check or wire transfer. Interest shall be payable in
Common Stock (as defined below) pursuant to paragraph 4(b) herein.

 

This
Note is subject to the following additional provisions:

 

This
Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the
Holder surrendering the same. No service charge will be made for such registration or transfer or exchange, except that Holder
shall pay any tax or other governmental charges payable in connection therewith.

 

2.                 
The Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

 

3.                 
This Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended ("Act")
and applicable state securities laws. Any attempted transfer to a non-qualifying party shall be treated by the Company as void.
Prior to due presentment for transfer of this Note, the Company and any agent of the Company may treat the person in whose name
this Note is duly registered on the Company's records as the owner hereof for all other purposes, whether or not this Note be
overdue, and neither the Company nor any such agent shall be affected or bound by notice to the contrary. Any Holder of this Note
electing to exercise the right of conversion set forth in Section 4(a) hereof, in addition to the requirements set forth in Section
4(a), and any prospective transferee of this Note, also is required to give the Company written confirmation that this Note is
being converted ("Notice of Conversion") in the form annexed hereto as Exhibit A. The date of receipt
(including receipt by telecopy) of such Notice of Conversion shall be the Conversion Date.

 

4.                 
(a) The Holder of this Note is entitled, at its option, at any time after 180 days, to convert all or any amount of the principal
face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a
price ("Conversion Price") for each share of Common Stock equal to 50% of the lowest trading price
of the Common Stock as reported on the National Quotations Bureau OTC MARKETS exchange which the Company’s shares
are traded or any exchange upon which the Common Stock may be traded in the future ("Exchange"), for the twenty
prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent
(provided such Notice of Conversion is delivered by fax or other electronic method of communication to the Company or its transfer
agent after 4 P.M. Eastern Standard or Daylight Savings Time if the Holder wishes to include the same day closing price). If the
shares have not been delivered within 3 business days, the Notice of Conversion may be rescinded. Such conversion shall be effectuated
by the Company delivering the shares of Common Stock to the Holder within 3 business days of receipt by the Company of the Notice
of Conversion. Accrued but unpaid interest shall be subject to conversion. No fractional shares or scrip representing fractions
of shares will be issued on conversion, but the number of shares issuable shall be rounded to the nearest whole share. To
the extent the Conversion Price of the Company’s Common Stock closes below the par value per share, the Company will take
all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law.
The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill”
on its shares, the conversion price shall be decreased to 40% instead of 50% while that “Chill” is in effect. If
the Company violates Section 4(e) of the Securities Purchase Agreement between the parties dated June 23, 2016, the conversion
price shall be 30% instead of 50% and the prepay premium under this Note shall increase to 170%. In no event shall the Holder
be allowed to effect a conversion if such conversion, along with all other shares of Company Common Stock beneficially owned by
the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. 

    	 	1	 

     

    

 

(b)              
Interest on any unpaid principal balance of this Note shall be paid at the rate of 8% per annum. Interest shall be paid by the
Company in Common Stock ("Interest Shares"). Holder may, at any time, send in a Notice of Conversion to the Company
for Interest Shares based on the formula provided in Section 4(a) above. The dollar amount converted into Interest Shares shall
be all or a portion of the accrued interest calculated on the unpaid principal balance of this Note to the date of such notice.

 

(c)              
This Note may not be prepaid, except that if the $56,000 Rule 144 convertible redeemable note issued by the Company of even date
herewith is redeemed by the Company within 6 months of the issuance date of such Note, all obligations of the Company under this
Note and all obligations of the Holder under the Holder Issued Note will each be automatically be deemed satisfied and this Note
and the Holder Issued Note will be automatically be deemed cancelled and of no further force or effect.

 

(d)              
Upon (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of
related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the
Common Stock, other than a forward or reverse stock split or stock dividend, or (iii) any consolidation or merger of the Company
with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected
solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of
outstanding shares of Common Stock solely into shares of Common Stock) (each of items (i), (ii) and (iii) being referred to as
a "Sale Event"), then, in each case, the Company shall, upon request of the Holder, redeem this Note in cash for 150%
of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election of the Holder, such
Holder may convert the unpaid principal amount of this Note (together with the amount of accrued but unpaid interest) into shares
of Common Stock immediately prior to such Sale Event at the Conversion Price.

 

(e)              
In case of any Sale Event (not to include a sale of all or substantially all of the Company’s assets) in connection with
which this Note is not redeemed or converted, the Company shall cause effective provision to be made so that the Holder of this
Note shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and number of shares
of stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization or other
change, consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise
of the Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The foregoing provisions
shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash,
the value shall be as deter- mined by the Board of Directors of the Company or successor person or entity acting in good faith.

 

    	 	2	 

     

    

 

5.                 
No provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the
principal of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

 

6.
                The Company hereby expressly waives
demand and presentment for payment, notice of non-payment, protest, notice of protest, notice of dishonor, notice of acceleration
or intent to accelerate, and diligence in taking any action to collect amounts called for hereunder and shall be directly and
primarily liable for the payment of all sums owing and to be owing hereto.

 

7.                 
The Company agrees to pay all costs and expenses, including reasonable attorneys' fees and expenses, which may be incurred by
the Holder in collecting any amount due under this Note.

 

8.
            If one or more of the following described "Events
of Default" shall occur:

 

(a)                The
Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company;
or

 

(b)                Any
of the material representations or warranties made by the Company herein or in any certificate or financial or other written statements
heretofore or hereafter furnished by or on behalf of the Company in connection with the execution and delivery of this Note, or
the Securities Purchase Agreement under which this note was issued shall be false or misleading in any respect; or

 

(c)                The
Company shall fail to perform or observe, in any respect, any material covenant, term, provision, condition, agreement or obligation
of the Company under this Note or any other note issued to the Holder; or

 

(d)                The
Company shall (1) admit in writing its inability to pay its debts generally as they mature; (2) make an assignment for the benefit
of creditors or commence proceedings for its dissolution; (3) apply for or consent to the appointment of a trustee, liquidator
or receiver for its or for a substantial part of its property or business; (4) file a petition for bankruptcy relief, consent
to the filing of such petition or have filed against it an involuntary petition for bankruptcy relief, all under federal or state
laws as applicable; or

 

(e)               A
trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without
its consent and shall not be discharged with- in sixty (60) days after such appointment; or

 

(f)                Any
governmental agency or any court of competent jurisdiction at the in- stance of any governmental agency shall assume custody or
control of the whole or any substantial portion of the properties or assets of the Company; or

 

(e)                Unless
the judgment or litigation has been previously disclosed in the Company’s filings with the Securities and Exchange Commission,
One or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars ($50,000)
in the aggregate, shall be entered against the Company or any of its properties or other assets and shall remain unpaid, unvacated,
unbonded or unstayed for a period of fifteen (15) days or in any event later than five (5) days prior to the date of any proposed
sale thereunder; or

    	 	3	 

     

    

 

		(h)	Intentionally
                                         Left Blank; or

 

(i)                The
Company shall have its Common Stock delisted from a trading market (including the OTC BB market or the OTC Markets) or, if the
Common Stock trades on an exchange, then trading in the Common Stock shall be suspended for more than 10 consecutive days or ceases
to file its 1934 act reports with the SEC;

 

		(j)	Intentionally
                                         Left Blank;

 

(k)              
The Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within
3 business days of its receipt of a Notice of Conversion; or

 

(l)                
The Company shall not replenish the reserve set forth in Section 12, with- in 5 business days of the request of the Holder; or

 

		(m)	The
                                         Company’s Common Stock has a closing bid price of less than $0.0003 per share for
                                         at least 5 consecutive trading days; or

 

(n)              
The aggregate dollar trading volume of the Company’s Common Stock is less than thirty thousand dollars ($30,000.00) in any
5 consecutive trading days; or

 

(o)              
The Company shall cease to be “current” in its filings with the Securities and Exchange Commission; or.

 

(p)              
The Company shall lose the “bid” price for its stock and a market (including the OTCBB marketplace or other exchange)

 

Then,
or at any time thereafter, unless cured (except for 8(m) and 8(n) which are incurable de- faults, the sole remedy of which
is to allow the Holder to cancel both this Note and the Holder Issued Note, and in each and every such case, unless such Event
of Default shall have been waived in writing by the Holder (which waiver shall not be deemed to be a waiver of any subsequent
default) at the option of the Holder and in the Holder's sole discretion, the Holder may consider this Note immediately due and
payable, without presentment, demand, protest or (further) notice of any kind (other than notice of acceleration), all of which
are hereby expressly waived, anything herein or in any note or other instruments contained to the contrary notwithstanding, and
the Holder may immediately, and without expiration of any period of grace, en- force any and all of the Holder's rights and remedies
provided herein or any other rights or reme dies afforded by law. Upon an Event of Default, interest shall accrue at a default
interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest
permitted by law. In the event of a breach of Section 8(k) the penalty shall be $250 per day the shares are not issued beginning
on the 4th day after the conversion notice was delivered to the Company. This penalty shall increase to $500 per day beginning
on the 10th day. The penalty for a breach of Section 8(p) shall be an increase of the outstanding principal amounts by 20%. In
case of a breach of Section 8(i), the outstanding principal due under this Note shall increase by 50%. Further, if a breach of
Section 8(o) occurs or is continuing after the 6 month anniversary of the Note, then the Holder shall be entitled to use the lowest
closing bid price dur- ing the delinquency period as a base price for the conversion. For example, if the lowest closing bid price
during the delinquency period is $0.01 per share and the conversion discount is 50% the Holder may elect to convert future conversions
at $0.005 per share. If this Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

    	 	4	 

     

    

 

If
the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging
an attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Company for its attorneys’
fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

 

Make-Whole
for Failure to Deliver Loss. At the Holder’s election, if the Company fails for any reason to deliver to the Holder the
conversion shares by the by the 3rd business day following the delivery of a Notice of Conversion to the Company and if the Holder
incurs a Failure to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable
to the Holder in respect of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

Failure
to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of conversion shares)]

 

The
Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day
from the time of the Holder’s written notice to the Company.

 

9.                 
In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid
or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent
possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired
thereby.

 

10.             
Neither this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed
by the Company and the Holder.

 

11.             
The Company represents that it is not a “shell” issuer and has never been a “shell” issuer or that if
it previously has been a “shell” issuer that at least 12 months have passed since the Company has reported form 10
type information indicating it is no longer a “shell issuer. The Company will instruct its counsel to either (i) write a
Rule 144 or similar opinion to allow for salability of the conversion shares or (ii) accept such opinion from Holder’s counsel,
provided such legal opinion is, in the reasonable determination of Company counsel, factually and legally correct.

    	 	5	 

     

    

 

12.           
Prior to cash funding of this Note, The Company will issue irrevocable transfer agent instructions reserving 3x the number of
shares of Common Stock necessary to allow the holder to convert this note based on the discounted conversion price set forth in
Section 4(a) herewith. The reserve shall be replenished as needed to allow for conversions of this Note using said 3x reserve.
Upon full conversion of this Note, the reserve representing this Note shall be cancelled. The Company will pay all transfer agent
costs associated with issuing and delivering the shares. If such amounts are to be paid by the Holder, it may deduct such amounts
from the Conversion Price. Conversion Notices may be sent to the Company or its transfer agent via electric mail.

 

13.             
The Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits,
recapitalizations etc. This notice shall be given to the Holder as soon as possible under law.

 

14.             
This Note shall be governed by and construed in accordance with the laws of New York applicable to contracts made and wholly to
be performed within the State of New York and shall be binding upon the successors and assigns of each party hereto. The Holder
and the Company hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue in the courts of the State
of New York or in the Federal courts sitting in the county or city of New York. This Agreement may be executed in counterparts,
and the facsimile transmission of an executed counterpart to this Agreement shall be effective as an original.

    	 	6	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed by an officer thereunto duly authorized.

  

Dated: 6/23/16 

 

 RICH
PHARMACEUTICALS, INC.

 

 By:
/s/ Ben Chang

 

Title:
CEO

    	 	7	 

     

    

EXHIBIT
A

 

 

NOTICE
OF CONVERSION

 

(To
be Executed by the Registered Holder in order to Convert the Note)

 

The
undersigned hereby irrevocably elects to convert $_____of the above Note into_____Shares of Common Stock of Rich Pharmaceuticals,
Inc. (“Shares”) according to the conditions set forth in such Note, as of the date written below.

 

If
Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer and other taxes
and charges payable with respect thereto.

 

Date
of Conversion: ____________________

Applicable
Conversion Price:  _____________________

Signature:
 _____________________

[Print
Name of Holder and Title of Signer]

Address:
 _____________________

_____________________

 

SSN
or EIN:  _____________________

Shares
are to be registered in the following name: _____________________

Name:
 _____________________ 

Address:
 _____________________

Tel:_____________________

Fax:
_____________________

SSN
or EIN:  _____________________

 

Shares
are to be sent or delivered to the following account:

 

Account
Name:  _____________________

Address:
 _____________________

    	 	8THIS
NOTE HAS NOT
BEEN REGISTERED UNDER
THE SECURITIES ACT
OF 1933, AS AMENDED
(THE "ACT"), OR
UNDER THE SECURITIES
LAWS OF CERTAIN
STATES. THESE SECURITIES ARE
SUBJECT TO RESTRICTIONS
ON TRANSFERABILITY AND RESALE
AND MAY NOT
BE TRANSFERRED OR
RESOLD EXCEPT AS
PERMITTED UNDER
THE ACT AND
THE APPLICABLE STATE
SECURITIES LAWS, PURSUANT
TO REGISTRATION OR EXEMPTION
THEREFROM. LENDERS SHOULD
BE AWARE THAT THEY MAY BE REQUIRED
TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE
EFFECT THAT ANY PROPOSED
TRANSFER OR RESALE IS
IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

LG
CAPITAL FUNDING,
LLC

COLLATERALIZED
SECURED PROMISSORY NOTE

 

 

	$56,000.00	Brooklyn,
                                         NY

                                              June
                                         23, 2016

		1.	Principal
                                         and Interest

 

FOR
VALUE RECEIVED, LG
Capital Funding, LLC,
a New York
Limited Liability Company (the
"Company") hereby absolutely
and unconditionally promises
to pay to
Rich Pharmaceuticals, Inc. (the
“Lender"), or order,
the principal amount
of Fifty Six
Thousand Dollars ($56,000.00) no
later than September
10, 2016, unless
the Lender does
not meet the
“current information requirements”
required under Rule
144 of the
Securities Act of
1933, as amended,
in which case the
Company may declare
the offsetting note
issued by the
Lender on the
same date herewith to
be in Default
(as defined in
that note) and
cross cancel its
payment obligations under
this Note as well
as the Lenders
payment obligations under
the offsetting note.
This Full Recourse
Note shall bear simple interest at the rate of 8%.

 

		2.	Repayments
                                         and Prepayments;
                                         Security.

 

a.                  
All principal under
this Note shall
be due and
payable no later
than September 10, 2016,
unless the Lender
does not meet
the “current information
requirements” required under
Rule 144 of
the Securities Act
of 1933, as
amended, in which
case the Company
may declare the offsetting
note issued by
the Lender on
the same date
herewith to be
in Default (as
defined in that note)
and cross cancel
its payment obligations
under this Note
as well as
the Lenders payment obligations
under the offsetting
note.

 

b.                 
The Company may
pay this Note
at any time.
This note may
not be assigned by
the Lender, except
by operation of
law.

 

c.                  
This Note shall
initially be secured
by the pledge
of the $56,000
8% convertible promissory note
issued to the
Company by the
Lender on even
date herewith (the “Lender
 Note”).  The 
Company  may  exchange
 this  collateral 
for  other  collateral 
with  an appraised value of
at least $56,000.00,
by providing 3
days prior written
notice to the
Lender. If the
Lender does not
object to
the substitution
of collateral in
that 3 day
period, such substitution
of collateral shall
be deemed to
have been accepted
by the Lender. Notwithstanding the
foregoing, an exchange of
collateral for $56,000.00 in cash
shall not require the approval of the Lender. All collateral shall be retained by New
Venture Attorneys, P.C., which shall act
as the escrow
agent for the collateral
for the benefit of the
Lender. The Company may not effect any conversions under the Lender Note until
it has made full cash payment for the portion of the Lender Note being converted.

    	 	1	 

     

    

 

		3.	Events
                                         of Default;
                                         Acceleration.

 

a.                  
The principal amount
of this Note
is subject to
prepayment in whole
or in part
upon the occurrence and
during the continuance
of any of
the following events
(each, an “Event
of Default”): the initiation
of any bankruptcy,
insolvency, moratorium, receivership
or reorganization by or
against the Company,
or a general
assignment of assets
by the Company
for the benefit
of creditors. Upon the
occurrence of any
Event of Default,
the entire unpaid
principal balance of
this Note and all
of the unpaid
interest accrued thereon
shall be immediately
due and payable.
The Company may offset amounts
due to the Lender
under this Note by similar
amounts that may be due to
the Company by
the Lender resulting
from breaches under
the Lender Note.

 

b.                 
No remedy herein
conferred upon the
Lender is intended
to be exclusive
of any other remedy
and each and
every remedy shall
be cumulative and
in addition to
every other remedy hereunder,
now or hereafter
existing at law
or in equity
or otherwise. The
Company accepts and agrees
that this Note
is a full
recourse note and
that the Holder
may exercise any
and all remedies available
to it under
law.

 

		4.	Notices.

 

a.                    
All notices, reports
and other communications
required or permitted
hereunder shall be in
writing and may
be delivered in
person, by telecopy
with written confirmation,
overnight delivery service or
U.S. mail, in
which event it
may be mailed
by first-class, certified
or registered, postage prepaid,
addressed (i) if
to a Lender,
at such Lender’s
address as the
Lender shall have furnished
the Company in
writing and (ii)
if to the
Company at such
address as the
Company shall have furnished
the Lender(s) in
writing.

 

b.                 
Each such notice,
report or other
communication shall for
all purposes under
this Note be treated
as effective or
having been given
when delivered if
delivered personally or,
if sent by mail,
at the earlier
of its receipt
or 72 hours
after the same
has been deposited
in a regularly maintained
receptacle for the
deposit of the
United States mail,
addressed and mailed
as aforesaid, or, if
sent by electronic
communication with confirmation,
upon the delivery
of electronic communication.

    	 	2	 

     

    

 

		5.	Miscellaneous.

a.                    
Neither this Note
nor any provisions
hereof may be
changed, waived, discharged
or terminated orally, but
only by a
signed statement in
writing.

 

b.                 
No failure or
delay by the
Lender to exercise
any right hereunder
shall operate as
a waiver thereof, nor
shall any single
or partial exercise
of any right,
power or privilege
preclude any other right,
power or privilege.
The provisions of
this Note are
severable and if
any one provision hereof
shall be held
invalid or unenforceable
in whole or
in part in
any jurisdiction, such
invalidity or unenforceability shall
affect only such
provision in such
jurisdiction. This Note
expresses the entire understanding
of the parties
with respect to
the transactions contemplated
hereby. The Company and every endorser and guarantor of this Note regardless
of the time, order or place of signing hereby waives presentment, demand,
protest and notice of every kind,
and assents to any extension or postponement of the time for payment or any other indulgence,
to any substitution, exchange or release of collateral, and to the addition or release of any other party or person primarily
or secondarily liable.

 

c.                  
If Lender retains an attorney
for collection of this Note, or
if any suit or
proceeding is brought for the
recovery of all,
or any part
of, or for
protection of the
indebtedness respected by
this Note, then the
Company agrees to
pay all costs
and expenses of
the suit or
proceeding, or any
appeal thereof, incurred by
the Lender, including
without limitation, reasonable
attorneys' fees.

 

d.                 
This Note shall
for all purposes
be governed by,
and construed in
accordance with the laws
of the State
of New York
(without reference to
conflict of laws).

 

e.                  
This Note shall
be binding upon
the Company's successors
and assigns, and
shall inure to the
benefit of the
Lender's successors and
assigns.

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the
Company has caused
this Note to
be executed by
its duly authorized officer
to take effect
as of the
date first hereinabove
written.

 

 

LG
CAPITAL FUNDING,
LLC

 

 

By:
/s/ Joseph Lerman

Title:
Manager

 

 

 APPROVED:

 

RICH
PHARMACEUTICALS, INC.

 

 By:
/s/ Ben Chang

 Title:
CEO

    	 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]